The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 03, 2021

Filed:

Jun. 10, 2015
Applicants:

Commissariat a L'energie Atomique ET Aux Energies Alternatives, Paris, FR;

Bio Modeling Systems Ou Bmsystems, Paris, FR;

Inventors:

Franck Mouthon, Paris, FR;

Mathieu Charveriat, Issy les Moulineaux, FR;

Jean-Philippe Deslys, Le Chesnay, FR;

François Iris, Chaville, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/00 (2006.01); A01N 43/46 (2006.01); A61K 31/55 (2006.01); A61K 31/196 (2006.01); A61K 31/4525 (2006.01); A61K 31/5513 (2006.01); A61K 31/551 (2006.01); A61K 31/165 (2006.01); A61K 31/135 (2006.01); A61K 31/137 (2006.01); A61K 31/343 (2006.01); A61K 31/56 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/196 (2013.01); A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61K 31/165 (2013.01); A61K 31/343 (2013.01); A61K 31/4525 (2013.01); A61K 31/551 (2013.01); A61K 31/5513 (2013.01); A61K 31/56 (2013.01); A61K 45/06 (2013.01);
Abstract

The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-β-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid. The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-β-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid.


Find Patent Forward Citations

Loading…